Medtronic Inc. (MDT)
MDT (NYSE:Health Services)
$52.92
-0.59
-1.10%
Today's Range: 52.45 - 53.25 |
MDT Avg Daily Volume: 4,729,000
| Last Update: 06/18/13 - 4:00 PM EDT |
| Volume: 5,610,441 |
| YTD Performance: 29.01%
|
| Open: $52.99 |
| Previous Close: $53.51 |
| 52 Week Range: $36.91 -
$53.83 |
| Oustanding Shares: 1,013,805,980 |
| Market Cap: 54,248,757,990 |
6-Month Chart
TheStreet Ratings Grade for MDT
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
8 |
7 |
7 |
8 |
| Moderate Buy |
0 |
0 |
0 |
0 |
| Hold |
13 |
11 |
11 |
11 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.24 |
2.22 |
2.22 |
2.16 |
| Latest Dividend: |
0.26 |
| Latest Dividend Yield: |
1.94% |
| Dividend Ex-Date: |
04/03/13 |
| Price Earnings Ratio: |
15.88 |
|
| Price Earnings Comparisons: |
| MDT |
Sector Avg. |
S&P 500 |
| 15.88 |
15.90 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
17.31%
|
39.41%
|
36.15%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
1.60 |
0.05 |
0.02 |
| Net Income |
-4.10 |
0.12 |
0.04 |
| EPS |
4.70 |
0.21 |
0.07 |
| Earnings for MDT: |
| EBITDA |
5.80B |
| Revenue |
16.59B |
|
Average Earnings Estimates
;Qtr (10/13);FY (04/14);FY (04/15)&HEADING_LIST1=Qtr (07/12);Qtr (10/12);FY (04/13);FY (04/14)) |
|
| Average Estimate |
$0.88 |
$0.92 |
$3.84 |
$4.10 |
| Number of Analysts |
15 |
15 |
18 |
16 |
| High Estimate |
$0.90 |
$0.93 |
$3.85 |
$4.20 |
| Low Estimate |
$0.87 |
$0.88 |
$3.82 |
$4.02 |
| Prior Year |
$0.85 |
$0.88 |
$3.75 |
$3.84 |
| Growth Rate (Year over Year) |
3.84% |
4.70% |
2.30% |
6.94% |
Jun 18, 2013 | 7:11 AM EDT
Wells Fargo Health Care Conference (Day 1 of 2) - 06/18/13 - 06/19/13 Boston, MA
May 22, 2013 | 8:22 AM EDT
Shares of MDT now seen reaching $56, according to Credit Suisse. Estimates also upped, given the company's new guidance. Neutral rating...
May 20, 2013 | 7:37 AM EDT
MDT's price target was raised to $57 given a higher peer group valuation, said Citigroup.
May 16, 2013 | 8:11 AM EDT
MDT was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $53 price target.
| Feb 26, 2013 | 2:45 PM EST
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
Feb 20, 2013 | 7:56 AM EST
MDT estimates were raised through 2015, BMO Capital said. Company continues to grow across the board. Outperform rating and new $52 pri...
Feb 14, 2013 | 7:27 AM EST
MDT was downgraded to Neutral, Lazard Capital Markets said. Stock is up 30% over the past 8 months and the company lacks near-term cata...
Jan 25, 2013 | 6:51 AM EST
MDT was downgraded from Buy to Hold, Wunderlich said. Valuation call, as the stock is up 13% year-to-date.
Jan 17, 2013 | 8:22 AM EST
MDT was upgraded from Neutral to Outperform Credit Suisse said. $50 price target. Company can grow faster than consensus expectations o...
Jan 07, 2013 | 7:11 AM EST
JPMorgan Global Healthcare Conference (Day 2 of 5) - 01/06/13 - 01/10/13 San Francisco, CA
